Bone Densitometer Market Analysis

Bone Densitometer Market Analysis

To get key market trends

  Download Free Sample

Based on technology, the bone densitometer market is segmented into axial bone densitometry and peripheral bone densitometry. The axial bone densitometry segment witnessed the largest revenue size of USD 160.2 million in 2022 and is estimated to cross USD 264.6 million by 2032. The most used method for determining bone density in the body is dual-energy X-ray absorptiometry (DEXA). Due to its great precision, ease of use, and safety for both adults and children, this equipment is frequently used for both central and peripheral bone mineral density (BMD) scans.
 

Osteopenia and osteoporosis are diagnosed with the help of dual-energy x-ray absorptiometry (DEXA or DXA). Additionally, high prevalence of osteoporosis among the population base, the rising adoption rate can be linked to dual-energy x-ray absorptiometry's ability to satisfy a variety of clinical needs.
 

Based on application bone densitometer market is bifurcated osteoporosis and osteopenia diagnosis, cystic fibrosis diagnosis, chronic kidney diseases diagnosis, rheumatoid arthritis diagnosis, body composition measurement. The osteoporosis and osteopenia segment is anticipated to reach USD 155.6 million by 2032. Osteoporosis and osteopenia are common conditions, especially among older adults. The increasing prevalence of these conditions drives the need for bone densitometry to accurately diagnose and monitor bone health. Additionally, bone densitometers play a crucial role in assessing fracture risk associated with osteoporosis and osteopenia. By measuring bone mineral density (BMD) at specific sites, such as the hip and spine, bone densitometry helps determine an individual's likelihood of experiencing fractures.
 

The bone densitometer market is segmented by end-use into hospitals, specialty centers, and others. Hospitals segment accounted for 49% of market share in 2022, due to the growing tendency of government health organizations to promote advanced diagnostic tools that provide rapid results is one of the primary factors. Hospitals are also utilising fully automated technologies that can identify this condition early in the existing setting.
 

Additionally, hospitals play a crucial role in the diagnosis and management of osteoporosis. Bone densitometry, particularly dual-energy X-ray absorptiometry (DXA), is the primary diagnostic tool for osteoporosis. Hospitals need bone densitometers to accurately assess bone mineral density (BMD) and evaluate fracture risk in patients. This information is vital for making treatment decisions and implementing preventive measures.
 

U.S. bone densitometer market size held more than USD 103.6 million in 2022, owing to different collaborative initiatives performed by various companies to increase their R&D capabilities and maintain high medical standards. The increasing use of modern technology in healthcare systems, as well as the expanding burden of chronic diseases, are driving the U.S. market growth.
 

For instance, the American Cancer Society estimates that there will be 3,910 new instances of bone and joint cancer in the U.S. in 2022, of which 1,750 will be in females and 2,160 will be in males. Since cancer cells and cancer-specific medications have negative effects on bone cells, cancer is a major cause of bone loss and fractures. Additionally, rising number of people affected with bone related disorders is boosting the demand for orthopaedic devices such as the bone densitometer system that aids in determining the risk of fractures, the rising incidence of cancer also contributes to the expansion of the market in the region.